Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment

Epcoritamab (Tepkinly, AbbVie) is indicated for 'the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy'.

The dosage schedule is available in the summary of product characteristics for epcoritamab.

The list price of epcoritamab is £547.33 for 1 vial of 4 mg/0.8 ml concentrate for solution for injection and £6,568.00 for 1 vial of 48 mg/0.8 ml solution for injection (excluding VAT; BNF online accessed September 2025).

The company has a commercial arrangement. This makes epcoritamab available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, Abbvie's Carbon Reduction Plan for UK carbon emissions is published on their policies webpage.